Ascendis Pharma A/S Revenue From Sale Of Goods
Ascendis Pharma A/S (ASND) reported Revenue From Sale Of Goods of EUR 683.57 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-11.
Financial Statements › Income Statement › Other Income
ifrs-full:RevenueFromSaleOfGoods · last filed 2026-02-11
- Ascendis Pharma A/S revenue from sale of goods for the quarter ending 2025-12-31 was 240.09M EUR, a 232.86% increase year-over-year.
- Ascendis Pharma A/S revenue from sale of goods for the quarter ending 2025-09-30 was 193.79M EUR, a 247.85% increase year-over-year.
- Ascendis Pharma A/S revenue from sale of goods for the quarter ending 2025-06-30 was 153.66M EUR, a 389.54% increase year-over-year.
- Ascendis Pharma A/S revenue from sale of goods for the quarter ending 2025-03-31 was 96.03M EUR, a 44.41% increase year-over-year.
| Period end | Revenue From Sale Of Goods 3 month | Revenue From Sale Of Goods 6 month | Revenue From Sale Of Goods 9 month | Revenue From Sale Of Goods 12 month |
|---|---|---|---|---|
| 2025-12-31 | 240.09M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | 433.88M EUR derived: sum of 2 quarters · filed 2026-02-11 | 587.54M EUR derived: sum of 3 quarters · filed 2026-02-11 | 683.57M EUR 20-F · filed 2026-02-11 |
| 2025-09-30 | 193.79M EUR 6-K · filed 2025-11-12 | 347.45M EUR derived: sum of 2 quarters · filed 2025-11-12 | 443.48M EUR 6-K · filed 2025-11-12 | 515.61M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-06-30 | 153.66M EUR 6-K · filed 2025-08-07 | 249.69M EUR 6-K · filed 2025-08-07 | 321.82M EUR derived: sum of 3 quarters · filed 2026-02-11 | 377.53M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2025-03-31 | 96.03M EUR 6-K · filed 2025-05-01 | 168.16M EUR derived: sum of 2 quarters · filed 2026-02-11 | 223.87M EUR derived: sum of 3 quarters · filed 2026-02-11 | 255.26M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-12-31 | 72.13M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | 127.84M EUR derived: sum of 2 quarters · filed 2026-02-11 | 159.23M EUR derived: sum of 3 quarters · filed 2026-02-11 | 225.73M EUR 20-F · filed 2026-02-11 |
| 2024-09-30 | 55.71M EUR 6-K · filed 2025-11-12 | 87.10M EUR derived: sum of 2 quarters · filed 2025-11-12 | 153.60M EUR 6-K · filed 2025-11-12 | 217.85M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | 31.39M EUR 6-K · filed 2025-08-07 | 97.89M EUR 6-K · filed 2025-08-07 | 162.14M EUR derived: sum of 3 quarters · filed 2026-02-11 | 209.10M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | 66.50M EUR 6-K · filed 2025-05-01 | 130.75M EUR derived: sum of 2 quarters · filed 2026-02-11 | 177.72M EUR derived: sum of 3 quarters · filed 2026-02-11 | 213.61M EUR derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | 64.25M EUR derived: 20-F 12 month − 6-K 9 month · filed 2026-02-11 | 111.22M EUR derived: sum of 2 quarters · filed 2026-02-11 | 147.11M EUR derived: sum of 3 quarters · filed 2026-02-11 | 178.66M EUR 20-F · filed 2026-02-11 |
| 2023-09-30 | 46.97M EUR 6-K · filed 2024-11-14 | 82.86M EUR derived: sum of 2 quarters · filed 2024-11-14 | 114.41M EUR 6-K · filed 2024-11-14 | 131.50M EUR derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | 35.90M EUR 6-K · filed 2024-09-03 | 67.45M EUR 6-K · filed 2024-09-03 | 84.53M EUR derived: sum of 3 quarters · filed 2025-02-12 | 96.78M EUR derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | 31.55M EUR 6-K · filed 2024-05-02 | 48.63M EUR derived: sum of 2 quarters · filed 2025-02-12 | 60.89M EUR derived: sum of 3 quarters · filed 2025-02-12 | 65.32M EUR derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | 17.08M EUR derived: 20-F 12 month − 6-K 9 month · filed 2025-02-12 | 29.34M EUR derived: sum of 2 quarters · filed 2025-02-12 | 33.77M EUR derived: sum of 3 quarters · filed 2025-02-12 | 35.66M EUR 20-F · filed 2025-02-12 |
| 2022-09-30 | 12.25M EUR 6-K · filed 2023-11-07 | 16.69M EUR derived: sum of 2 quarters · filed 2023-11-07 | 18.57M EUR 6-K · filed 2023-11-07 | 19.52M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-06-30 | 4.43M EUR 6-K · filed 2023-09-05 | 6.32M EUR 6-K · filed 2023-09-05 | 7.27M EUR derived: sum of 3 quarters · filed 2024-02-07 | 7.27M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2022-03-31 | 1.89M EUR 6-K · filed 2023-04-27 | 2.83M EUR derived: sum of 2 quarters · filed 2024-02-07 | 2.83M EUR derived: sum of 3 quarters · filed 2024-02-07 | 2.83M EUR derived: sum of 4 quarters · filed 2024-02-07 |
| 2021-12-31 | 943.00K EUR derived: 20-F 12 month − 6-K 9 month · filed 2024-02-07 | 943.00K EUR derived: sum of 2 quarters · filed 2024-02-07 | 943.00K EUR derived: sum of 3 quarters · filed 2024-02-07 | 943.00K EUR 20-F · filed 2024-02-07 |
| 2021-09-30 | 0.00 EUR 6-K · filed 2022-11-02 | 0.00 EUR derived: sum of 2 quarters · filed 2022-11-02 | 0.00 EUR 6-K · filed 2022-11-02 | |
| 2021-06-30 | 0.00 EUR 6-K · filed 2022-08-10 | 0.00 EUR 6-K · filed 2022-08-10 | ||
| 2021-03-31 | 0.00 EUR 6-K · filed 2022-05-11 |